EVEON announces the launch of the European project INDENEO to develop an innovative delivery system for nose to brain administration of biological and advanced therapy drugs to neonates.

EVEON is exploring the Asian medical device market, including South Korea and Japan, as part of the French Healthcare Booster.

Over the course of 2021, EVEON made significant developments and broadened its range.

Our medical device Intuity® Spray received an award at the Pharmapack 2021 exhibition in the exhibitor - administration mode category.

EVEON has developed Ad-Mist™, an airless spray nozzle that can be used to produce fine droplets in the form of a mist. 

Article OnDrugDelivery about the gap between patient safety and HealthCareWorkers for product preparation. And How safe and automatic, such as EVEON devices, can improve drug preparationCheckout our last article for multidose vials?

EVEON has signed a collaboration agreement with BEPATIENT to produce patient-centric digital solutions that serve both clinical research and digital therapeutics applications.

EVEON is proposing to automate and deliver multidose drugs from a vial, as well as vaccines used in the context of the Covid-19 pandemic.

EVEON carried out many innovative projects in 2020. This new year is also promising for the company driven forward by this positive dynamics.

EVEON contributes to studies about feasibility of intratumoral delivery to induced glioblastoma, in a large animal model. EVEON developed the preclinical injection system for this project. Work on this subject has been published in the journal Plos One.